Platelets >= 100,000/mm^3, within 14 days before the first dose of cabozantinib
Hemoglobin >= 9 g/dL, within 14 days before the first dose of cabozantinib
Serum albumin >= 2.8 g/dl, within 14 days before the first dose of cabozantinib
Clinical MRIs performed at baseline must be completed within 28 days before the first dose of cabozantinib
Platelets >= 100,000/mm^3 within 7 days before the first dose of cabozantinib
Hemoglobin >= 9 g/dL within 7 days before the first dose of cabozantinib
Serum albumin >= 2.8 g/dl within 7 days before the first dose of cabozantinib
Prior treatment with cabozantinib
Prior treatment with cabozantinib (XL184)
Obtained within 28 days prior to the first dose of cabozantinib: platelets >= 100,000/mm^3.
Obtained within 28 days prior to the first dose of cabozantinib: hemoglobin >= 9 g/dL.
Obtained within 28 days prior to the first dose of cabozantinib: serum albumin >= 2.8 g/dl.
Obtained within 28 days prior to the first dose of cabozantinib: calcium >= 8 mg/dL.
Obtained within 28 days prior to the first dose of cabozantinib: magnesium >= 1.2 mg/dL.
Obtained within 28 days prior to the first dose of cabozantinib: potassium >= 3.0 meq/L.
Prior treatment with cabozantinib or other cMET inhibitors.
Prior treatment with cabozantinib or erlotinib
Patients must have completed their most recent drug therapy directed at multiple myeloma in the following timeframes:\r\n* Chemotherapy, biological therapy, immunotherapy, or an investigational therapy at least 3 weeks prior to starting cabozantinib\r\n* Corticosteroids at least 3 weeks prior to starting cabozantinib, except for a dose equivalent to dexamethasone of =< 4 mg/day\r\n* Nitrosoureas, nitrogen mustards, mitomycin C, or monoclonal antibodies at least 6 weeks prior to starting cabozantinib\r\n* Autologous stem cell transplantation at least 12 weeks prior to starting cabozantinib\r\n* Allogeneic stem cell transplantation at least 24 weeks prior to starting cabozantinib, and these patients must also not have moderate to severe active acute or chronic graft versus host disease
Patients who have undergone any recent major surgery must have done so at least 4 weeks prior to starting therapy with cabozantinib, with the following exceptions:\r\n* Vertebroplasty and/or kyphoplasty, which must have been performed at least 1 week prior to starting cabozantinib\r\n* Planned elective surgery unrelated to the patient’s diagnosis of multiple myeloma, such as hernia repair, may be allowed, at the discretion of the principle investigator, as long as it was performed at least 2 weeks prior to starting cabozantinib, and patients have\r\nrecovered fully from this procedure
Patients who have required plasmapheresis and exchange less than 2 weeks prior to initiation of therapy with cabozantinib
Has had prior treatment with cabozantinib
Patients with previous history of vandetanib or cabozantinib treatment for more than 28 days of treatment (patients have discontinued treatment for 28 days before enrolling)
Patients should be excluded if they have had prior treatment with cabozantinib; previous use of other antiangiogenic agents other than cabozantinib is allowed
Subjects who have received cabozantinib or have an allergy to cabozantinib are excluded; subjects who have previously received tyrosine kinase inhibitors are allowed
Prior treatment with cabozantinib
Within 4 days prior to the first dose of cabozantinib: Platelets >= 100,000/mm^3
Within 4 days prior to the first dose of cabozantinib: Hemoglobin >= 9 g/dL
Within 4 days prior to the first dose of cabozantinib: Serum albumin >= 2.8 g/dl
Within 4 days prior to the first dose of cabozantinib: Serum magnesium >= 1.2 mg/dL
Prior treatment with cabozantinib
Prior treatment with cabozantinib or other c-MET directed therapy
Prior treatment with cabozantinib
Within 7 days before the first dose of cabozantinib: Platelets >= 100,000/mm^3
Within 7 days before the first dose of cabozantinib: Hemoglobin >= 9 g/dL
Within 7 days before the first dose of cabozantinib: Serum albumin >= 2.8 g/dl
Prior treatment with cabozantinib
Subject has had prior treatment with cabozantinib
Prior cabozantinib treatment.
Prior treatment with cabozantinib
Prior treatment with cabozantinib
Prior treatment with cabozantinib
Prior treatment with cabozantinib
No prior therapy with cabozantinib
Prior treatment with a MET inhibitor (e.g. foretinib, crizotinib, cabozantinib, onartuzumab or previous savolitinib) or sunitinb.
Patient must have failed (progressed on or been intolerant of) prior treatment with cabozantinib or vandetanib
Prior treatment with cabozantinib and other met inhibitors
Subject has had prior treatment with cabozantinib
Prior treatment with cabozantinib
Prior treatment with cabozantinib (or other MET inhibitor) or CB-839